tuberculosi
tb
still
major
infecti
diseas
threaten
public
health
worldwid
especi
develop
countri
epidem
situat
tb
allevi
slowli
world
health
organ
estim
million
preval
case
million
incid
case
tb
world
million
peopl
die
tb
china
second
highest
tb
burden
countri
million
preval
case
record
earli
diagnosi
import
control
tb
biomark
play
irreplac
role
earli
diagnosi
diseas
surveil
treatment
efficaci
prognost
evalu
diseas
detect
biomark
also
conveni
sensit
specif
noninvas
reproduc
inexpens
method
present
effect
biomark
earli
diagnosi
tb
therefor
use
new
technolog
discov
verifi
sensit
specif
biomark
earli
diagnosi
tb
major
challeng
urgent
task
diseas
control
detect
biomark
serum
effect
auxiliari
mean
diagnosi
diseas
invas
mycobacterium
tuberculosi
mtb
human
bodi
chang
express
tbassoci
protein
releas
protein
bloodstream
differ
pathway
detect
serum
antibodi
tb
patient
precis
base
principl
howev
tb
antigen
vari
complex
antibodi
tb
patient
may
show
great
varieti
biomark
singl
antigen
recogn
serum
tb
patient
therefor
high
sensit
specif
achiev
emerg
proteom
technolog
make
analysi
protein
serum
possibl
surfaceenhanc
laser
desorpt
ioniz
time
flight
mass
spectrometri
selditof
ms
power
proteom
technolog
integr
technolog
chipsmagnet
bead
mass
spectrometri
directli
use
detect
crude
bodi
fluid
sampl
without
label
technolog
simpl
fast
highthroughput
high
sensit
mani
protein
biomark
certain
diseas
indic
use
selditof
ms
analyz
serum
proteom
goal
studi
screen
potenti
protein
biomark
serum
earli
diagnosi
tb
use
proteom
technolog
collect
serum
sampl
patient
activ
pulmonari
tb
control
healthi
volunt
case
lung
cancer
case
pneumonia
case
chronic
obstruct
pulmonari
diseas
copd
two
separ
site
sixth
hospit
shaox
shaox
china
hangzhou
red
cross
hospit
hangzhou
china
tb
patient
diagnos
accord
combin
clinic
criteria
includ
clinic
radiolog
bacteriolog
investig
confirm
histopatholog
analysi
blood
specimen
collect
preserv
upon
first
visit
treatment
patient
hepat
renal
metabol
autoimmun
disord
endocrin
blood
nervou
system
diseas
malign
tumor
longterm
use
immunosuppress
agent
includ
experi
patient
control
ethnic
han
popul
live
region
southeast
china
studi
approv
ethic
committe
faculti
medicin
zhejiang
univers
china
inform
consent
obtain
subject
collect
blood
peripher
blood
sampl
collect
tb
patient
control
earli
morn
without
anticoagul
blood
sampl
allow
clot
hour
prior
g
centrifug
minut
separ
serum
serum
sampl
aliquot
store
futur
analysi
sampl
pretreat
proteom
analysi
process
serum
sampl
diseas
control
group
random
investig
blind
clinic
manifest
serum
sampl
pretreat
wcx
magnet
bead
beij
sed
scienc
technolog
china
briefli
wcx
magnet
bead
preactiv
bind
buffer
mmoll
sodium
acet
ph
magnet
separ
serum
sampl
first
dilut
solut
moll
urea
chap
dimethylammonio
incub
minut
denatur
serum
sampl
dilut
bind
buffer
dilut
serum
sampl
ad
activ
magnet
bead
mix
incub
hour
bead
wash
twice
bind
buffer
remov
nonselect
bound
protein
follow
bind
wash
bound
protein
elut
magnet
bead
use
trifluoroacet
acid
elut
sampl
dilut
spa
satur
solut
sinapin
acid
sa
acetonitril
trifluoroacet
acid
next
result
mixtur
aspir
spot
onto
prestructur
sampl
auchip
air
dri
protein
crystal
chip
scan
proteinchip
reader
model
pb
iic
ciphergen
biosystem
usa
determin
mass
intens
peak
reader
set
follow
mass
rang
set
da
optim
mass
rang
set
da
laser
intens
set
laser
sensit
set
allinon
protein
standard
ii
biorad
usa
use
obtain
protein
standard
spectra
mass
accuraci
calibr
profil
spectra
serum
sampl
train
set
normal
use
total
ion
current
normal
ciphergen
proteinchip
softwar
version
peak
label
perform
biomark
wizard
softwar
version
ciphergen
biosystem
twosampl
ttest
use
compar
mean
normal
intens
case
control
group
protein
low
pvalu
select
intens
select
peak
transfer
biomark
pattern
softwar
bp
ciphergen
biosystem
construct
classif
tree
tb
briefli
intens
select
peak
submit
bp
root
node
base
peak
intens
threshold
determin
bp
classifi
root
node
two
child
node
sampl
would
label
leftsid
child
node
peak
intens
blind
sampl
lower
equal
threshold
meanwhil
peak
intens
higher
threshold
would
mark
rightsid
child
node
round
decisionmak
train
set
found
discriminatori
least
error
protein
peak
intens
sampl
test
set
evalu
bp
use
classif
model
tb
control
sampl
discrimin
base
proteom
profil
characterist
sensit
defin
probabl
predict
tb
case
specif
defin
probabl
predict
control
sampl
accuraci
defin
proport
correct
state
classif
serum
sampl
tb
patient
control
select
purif
candid
protein
biomark
serum
sampl
mix
acetonitril
acn
water
minut
centrifug
g
minut
supernat
fluid
collect
lyophil
dri
obtain
volum
solut
purif
use
rphplc
hplc
separ
perform
use
shimadzu
japan
pah
column
mm
welch
materila
inc
md
usa
guard
column
mm
shimadzu
japan
mobil
phase
consist
solvent
water
tfa
solvent
b
acn
tfa
hplc
separ
achiev
linear
solvent
gradient
min
b
min
b
min
b
min
b
min
b
min
flow
rate
mlmin
eluat
emiss
detect
multipl
wavelength
nm
peak
fraction
collect
analyz
use
aximacfrtm
plu
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
krato
analyt
co
uk
linear
mode
trace
candid
protein
biomark
sa
matrix
target
peptid
contain
fraction
obtain
use
analysi
lcmsm
target
peptid
contain
fraction
obtain
load
onto
homemad
column
mm
pack
sunchron
pack
materi
follow
nanolcesimsm
analysi
without
digest
ltq
mass
spectromet
thermo
finnigan
usa
oper
datadepend
mode
initi
ms
scan
record
mz
ratio
ion
mass
rang
da
firstli
five
abund
ion
automat
select
subsequ
collisionactiv
dissoci
msm
data
search
use
sequest
algorithm
human
protein
databas
download
ncbi
search
perform
use
precursor
mass
toler
amu
calcul
use
averag
isotop
mass
fragment
ion
toler
amu
variabl
modif
set
methionin
addit
da
repres
methionin
oxid
enzym
cleavag
specif
set
enzym
sequest
output
analyz
use
commerci
softwar
thermofish
biowork
filter
set
peptid
follow
xcorr
delta
cn
sp
rsp
serum
concentr
fdp
measur
enzymelink
immunosorb
assay
elisa
fdp
serum
sampl
quantifi
use
human
fibrinogen
degrad
product
elisa
kit
tsz
scientif
usa
follow
manufactur
instruct
test
serum
sampl
dilut
dilut
buffer
suppli
dilut
human
fdp
standard
test
sampl
ad
duplic
well
microtit
plate
coat
human
fdp
antibodi
fibrinogen
concentr
plasma
measur
clauss
method
use
kit
diagnost
stago
franc
coagul
stago
compact
autom
analyz
diagnost
stago
franc
determin
detect
case
tb
recruit
randomli
first
hospit
jiax
jiax
china
mean
age
gender
distribut
similar
tb
nontb
control
group
p
differ
found
number
individu
bcg
vaccin
hivneg
two
group
p
tabl
detail
characterist
tb
group
shown
tabl
tb
patient
show
differ
chang
inflamm
opac
fibrosi
caviti
chest
xray
sputum
cultur
patient
tb
posit
subject
bacteriolog
analysi
upon
first
visit
hospit
patient
neg
sputum
cultur
pathogen
identifi
patient
tb
brush
biopsi
bronchoalveolar
lavag
biopsi
diseas
pulmonari
segment
fiberopt
bronchoscop
typic
histopatholog
chang
tb
identifi
patient
tb
percutan
transthorac
needl
biopsi
comprehens
diagnosi
combin
clinic
symptom
fever
cough
expector
hemoptysi
radiolog
chang
chest
xray
antituberculosi
antibodi
detect
molecular
biolog
techniqu
detect
pathogenspecif
sequenc
patient
tb
receiv
antituberculosi
treatment
confirm
base
treatment
respons
tb
patient
involv
studi
follow
one
year
confirm
reliabl
result
subject
tb
nontb
control
group
randomli
divid
two
set
train
set
blind
test
set
tabl
characterist
two
set
test
statist
signific
ensur
noth
outsid
main
differenti
factor
confound
result
analyz
varianc
mz
peak
intens
calibr
smooth
align
normal
coeffici
variat
cv
found
less
select
mass
peak
addit
file
figur
protein
peak
per
spot
detect
mz
mz
protein
peak
show
effect
seldi
technolog
combin
wcx
magnet
bead
separ
lowmolecular
weight
protein
figur
protein
profil
serum
sampl
train
set
case
tb
case
lung
cancer
case
pneumonia
case
copd
healthi
volunt
analyz
biomark
wizard
softwar
mz
peak
found
discrimin
patient
tb
nontb
control
subject
p
fold
tabl
among
peak
downregul
upregul
patient
tb
compar
nontb
control
subject
accord
variabl
import
mz
peak
import
four
peak
select
bp
construct
classif
tree
figur
figur
show
tree
structur
sampl
distribut
classif
tree
use
combin
four
peak
identifi
patient
tb
nontb
control
calcul
sensit
specif
overal
accuraci
use
sampl
blind
test
set
includ
patient
tb
case
lung
cancer
case
pneumonia
case
copd
case
healthi
volunt
test
tb
diagnost
model
classif
tree
discrimin
tb
sampl
control
sampl
accuraci
sensit
specif
tabl
serum
sampl
use
purif
candid
protein
biomark
use
acn
rphplc
result
malditof
ms
analysi
show
one
target
peptid
contain
peak
fraction
also
contain
four
peptid
figur
even
detect
selditofm
peptid
mixtur
analyz
nanolcmsm
figur
three
major
peptid
identifi
fragment
protein
fibrinogen
alpha
polypeptid
isoform
alpha
preproprotein
homo
sapien
mass
tabl
small
peptid
also
identifi
fragment
fibrinogen
fraction
shown
tabl
evalu
fdp
level
serum
elisa
done
serum
patient
tb
healthi
volunt
select
randomli
test
set
level
fdp
tb
group
higher
healthi
group
vs
ngml
p
figur
measur
plasma
fibrinogen
level
tb
patient
clauss
method
use
confirm
tb
case
detail
characterist
shown
tabl
result
show
higher
level
plasma
fibrinogen
patient
tb
gl
compar
normal
group
gl
pathogen
mechan
patholog
chang
caus
mtb
invas
human
base
protein
express
proteinprotein
interact
host
defens
system
trigger
mainli
immuneinflammatori
respons
tb
infect
lead
synthesi
tbassoci
protein
appear
blood
circul
varieti
pathway
direct
secret
protein
lesion
affect
mtb
stimul
product
reactiv
protein
product
protein
due
disintegr
mtb
tbassoci
protein
use
potenti
diagnost
marker
discrimin
tb
patient
biomark
research
selditof
ms
aim
identifi
peak
intens
differ
case
control
sampl
reproduc
peak
intens
highest
import
howev
poor
reproduc
consid
one
problem
selditof
ms
studi
strict
standard
oper
procedur
intern
extern
control
combin
data
qualiti
reproduc
intern
control
method
one
point
randomli
select
au
chip
perform
experi
qualiti
control
serum
allinon
protein
standard
ii
use
extern
control
obtain
protein
standard
spectra
mass
accuraci
calibr
tb
control
sampl
detect
selditof
ms
use
batch
magnet
bead
auchip
equip
procedur
follow
within
one
week
ensur
experiment
repeat
reliabl
total
discrimin
mz
peak
detect
relat
tb
p
fold
model
base
four
biomark
da
establish
could
distinguish
tb
patient
control
blind
test
set
result
yield
sensit
specif
compar
previou
similar
studi
candid
marker
found
one
possibl
reason
may
use
differ
type
magnet
bead
detect
method
previou
studi
adopt
weak
cation
exchang
protein
chip
applic
seldi
technolog
tb
biomark
discoveri
present
studi
appli
wcx
magnet
bead
although
weakli
cation
new
protein
separ
technolog
wcx
magnet
bead
provid
great
flexibl
fraction
complex
biolog
sampl
success
use
separ
purif
variou
protein
bodi
fluid
serum
plasma
amniot
fluid
pilot
studi
compar
seldi
spectra
serum
tb
patient
wcx
magnet
bead
protein
chip
result
show
wcx
magnet
bead
could
screen
protein
serum
sampl
tb
patient
higher
accuraci
protein
peak
stronger
abil
protein
captur
figur
therefor
wcx
magnet
bead
use
discov
new
protein
biomark
serum
anoth
reason
may
differ
racial
genet
factor
studi
report
agranoff
et
al
tb
patient
case
tb
group
african
patient
major
control
group
caucasian
might
result
bia
studi
attempt
find
new
tb
diagnost
marker
chines
han
popul
meanwhil
candid
protein
marker
identifi
studi
pilot
studi
tri
adsorpt
method
enrich
use
wcx
magnet
bead
acn
precipit
method
final
acn
precipit
method
acn
serum
ratio
use
serum
sampl
precipit
could
enrich
major
lowmolecularweight
protein
peptid
supernat
track
malditof
ms
target
peptid
purifi
analyz
nanolcmsm
one
candid
peptid
peak
da
two
peptid
da
identifi
fragment
fibrinogen
alpha
polypeptid
isoform
alpha
preproprotein
homo
sapien
mass
indic
level
fdp
tb
patient
group
may
higher
nontb
group
studi
result
show
higher
level
fdp
tb
patient
vs
ngml
p
healthi
volunt
robson
et
al
studi
hemostat
profil
patient
acut
tb
report
increas
fdp
level
experiment
result
consist
increas
fdp
blood
tb
patient
indic
fibrinolyt
system
activ
one
possibl
reason
fibrinolyt
system
activ
increas
fibrinogen
level
blood
activ
fibrinogenas
fibrinolyt
system
enter
blood
larg
quantiti
caus
increas
fdp
serum
part
bodi
defens
function
robson
et
al
report
increas
fdp
level
concurr
elev
level
fibrinogen
fibrinogen
acutephas
reactant
product
rate
may
increas
greatli
result
variou
essenti
nonspecif
stimuli
turken
et
al
studi
hemostat
chang
activ
pulmonari
tb
found
elev
plasma
fibrinogen
level
appear
induc
hypercoagul
state
other
also
report
significantli
higher
level
plasma
fibrinogen
nigeria
pulmonari
tb
patient
similarli
studi
analysi
patient
tb
show
increas
plasma
fibrinogen
level
gl
postul
vascular
endothelium
could
prime
result
interact
mycobacteri
product
host
monocytemacrophag
system
synthesi
larg
amount
cytokin
tumor
necrosi
factoralpha
cytokin
induc
hepat
acutephas
respons
alter
level
coagul
protein
fibrinogen
addit
report
plasminogen
plg
member
fibrinolyt
system
bound
immobil
microb
surfac
plg
receptor
activ
host
pathogen
activ
gener
proteolyt
enzym
plasmin
plm
turn
microb
proteolyt
organ
therebi
augment
invas
potenti
bacteria
also
exploit
molecul
fibrinolyt
system
avoid
innat
immun
respons
fibrinolyt
system
modul
inflammatori
respons
induc
pathogen
mtb
demonstr
high
number
plg
receptor
activ
plm
host
activ
suggest
interact
could
role
hostbacteria
relationship
therefor
specul
activ
fibrinolyt
system
close
associ
onset
progress
tb
studi
blind
test
diagnost
model
tb
yield
sensit
specif
result
show
tb
patient
sensit
diagnost
model
case
fals
neg
addit
technic
method
statist
discrep
lack
gold
standard
diagnosi
case
clearli
limit
studi
tb
case
cultur
posit
proven
case
minor
cultur
neg
case
may
tb
although
patient
neg
sputum
cultur
diagnos
base
comprehens
combin
clinic
radiolog
find
tb
treatment
outcom
may
pulmonari
infecti
diseas
may
mimic
pulmonari
tb
meanwhil
upregul
peak
mz
identifi
fragment
fibrinogen
studi
signific
minor
case
dataset
use
identifi
biomark
defin
diagnost
gold
standard
larg
sampl
clinic
studi
sputum
cultur
gold
standard
diagnosi
tb
model
construct
use
protein
peak
mz
could
success
distinguish
tb
patient
control
peak
mz
identifi
fragment
fibrinogen
addit
found
increas
level
fibrinogen
fdp
tb
patient
reflect
activ
fibrinolyt
system
anoth
perspect
although
experi
larger
studi
indispens
prove
reliabl
protein
identifi
studi
result
help
diagnost
evalu
respons
therapi
patient
tb
author
declar
compet
interest
jcl
conceiv
studi
design
experi
jl
tj
lw
xy
xz
collect
serum
sampl
jl
j
cw
zc
dx
analyz
data
suggest
jcl
jl
fy
finish
mass
spectrometri
analysi
jl
jcl
wrote
manuscript
author
read
approv
final
manuscript
prepubl
histori
paper
access
http
